
From: Executive Assistant <Executive.Assistant@medicinesaustralia.com.au>
Sent: Friday, 28 January 2022 4:42 PM
To: Exemptions; Mitchell, Sophie; Jones, Gavin
Cc: [REDACTED]
Subject: Medicines Australia-ACCC Interim Authorisation- AA1000579-Monthly report-30 December 2021 to 29 January 2022

Dear ACCC Exemptions Team,

In relation to the ACCC Interim Authorisation AA1000579 (29 September 2021) and, specifically, in accordance with the Conditions of that Authorisation at paragraph 23, Medicines Australia provides the following monthly report on activities related to the Proposed Conduct.

In the period of 30 December 2021 to 29 January 2022, no meeting, discussion, development or decision between MA/GBMA Working Group members in relation to the Proposed Conduct took place, other than the meeting that occurred on 29 September 2021, which was the subject of the report by Medicines Australia, lodged with the ACCC on 5 October 2021 under the then current authorisation (AA1000486).

Medicines Australia's next monthly update will cover the period of 30 January 2022 to 28 February 2022. Additional updates will be provided to the ACCC as required and in accordance with Medicines Australia's obligations under the authorisation.

We also consent to this email being published on the public register, with the appropriate privacy redactions.

This response was drafted by Medicines Australia in consultation with [REDACTED], CEO of Generic and Biosimilar Medicines Association.

Yours sincerely

[REDACTED]

[REDACTED]
Senior Executive Assistant

[REDACTED] | [REDACTED]
📍 17 Denison Street, Deakin ACT 2606



In the spirit of reconciliation Medicines Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.